Search

Displaying results 4171 - 4180 of 10000 in total
  1. Drug

    Diaziquone

    go.drugbank.com/drugs/DB17174
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Phosphocysteamine

    go.drugbank.com/drugs/DB17640
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom. … TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.

  4. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  5. Drug

    Tetradecylthioacetic acid

    go.drugbank.com/drugs/DB18802
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Patulin

    go.drugbank.com/drugs/DB15586
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Dihydrolipoic Acid

    go.drugbank.com/drugs/DB03760
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Dodecyl sulfate

    go.drugbank.com/drugs/DB03967
    Investigational

    Synonyms: N-Dodecyl sulfateCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  10. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure